Polymorphism in candidate genes: Implications for the risk and treatment of idiopathic Parkinson's disease

Pharmacogenomics Journal

Volumn 4, Issue 5, 2004, Pages 291-306

  Gilgun Sherki, Y ^a,b   Djaldetti, Ruth ^a,b   Melamed, E ^a,b   Offen, D ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Dopamine; Dyskinesia; Levodopa; Parkinson's disease; Polymorphism; Single nucleotide polymorphism (SNP)

Indexed keywords

ACYLTRANSFERASE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING); APOLIPOPROTEIN E; BENSERAZIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; DOPAMINE BETA MONOOXYGENASE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE TRANSFERASE; LEVODOPA; NUCLEAR RECEPTOR RELATED FACTOR 1; RASAGILINE; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

BLOOD BRAIN BARRIER; DISEASE PREDISPOSITION; DOPAMINE METABOLISM; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DYSKINESIA; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; IDIOPATHIC DISEASE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VISUAL HALLUCINATION;

HUMANS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 5144226037     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500260     Document Type: Review

References (200)

1. Morrish PK, Sawle GV, Brooks DJ. The rate of progression of Parkinson's disease: a longitudinal [18F] DOPA PET study. In: Battistin L, Scarlato G, Caraceni T et al (eds). Advances in Neurology, Vol 69 Lippincott-Raven Publishers: Philadelphia (PA) 1996; pp 427-431.
2. Leenders KL. Pathophysiology of movement disorders studied using PET. J Neural Transm Suppl 1997; 50: 39-46.
3. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177-182.
4. Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am 1997; 20: 821-838.
5. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49: 717-723.
6. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 1989; 84: 9762-9766.
7. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990; 347: 80-83.
8. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614.
9. Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godinot N et al. Cloning, molecular characterization and chromosomal assignment of a gene encoding a second D1 receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci USA 1991; 88: 7491-7495.
10. Le Coniat M, Sokoloff P, Hillion J, Martres MP, Giros B, Pilon C et al. Chromosomal localization of the human D3 dopamine receptor gene. Hum Genet 1991; 87: 618-620.
11. Schwartz JC, Giros B, Martres MP, Sokoloff P. The dopamine receptor family: molecular biology and pharmacology. Semin Neurosci 1992; 4: 99-108.
12. Higuchi S, Muramatsu T, Arai H, Hayashida M, Sasaki H, Trojanowski JQ. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 1995; 10: 107-113.
13. Oliveri RL, Annesi G, Zappia M, Civitelli D, De Marco EV, Pasqua AA et al. The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Mov Disord 2000; 15: 127-131.
14. Grevle L, Guzey C, Hadidi H, Brennersted R, Idle JR, Aasly J. Allelic association between the DRD2 Taql A polymorphism and Parkinson's disease. Mov Disord 2000; 15: 1070-1074.
15. Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266: 1793-1800.
16. Costa-Mallen P, Costa LG, Smith-Weller T, Franklin GM, Swanson PD, Checkoway H. Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAOB intron 13 polymorphism. J Neurol Neurosurg Psychiatry 2000; 69: 535-537.
17. Nanko S, Ueki A, Hattori M, Dai XY, Sasaki T, Fukuda R et al. No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms. Am J Med Genet 1994; 54: 361-364.
18. Plante-Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD et al. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997; 48: 1589-1593.
19. Pastor P, Munoz E, Obach V, Marti MJ, Blesa R, Oliva R et al. Dopamine receptor D2 intronic polymorphism in patients with Parkinson's disease. Neurosci Lett 1999; 273: 151-154.
20. Oliveri RL, Annesi G, Zappia M, Civitelli D, Montesanti R, Branca D et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999; 53: 1425-1430.
21. Wan DC, Law LK, Ip DT. Cheung WT, Ho WK, Tsim KW et al. Lack of allelic association of dopamine D4 receptor gene polymorphisms with Parkinson's disease in a Chinese population. Mov Disord 1999; 14: 225-229.
22. Kronenberg MF, Menzel HJ, Ebersbach G, Wenning GK, Luginger E, Gollner M et al. Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. Eur J Hum Genet 1999; 7: 397-400.
23. Ricketts MH, Hamer RM, Manowitz P, Feng F, Sage JI, Di Paola R et al. Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease. Clin Genet 1998; 54: 33-38.
24. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533-538.
25. Kitayama S, Shimada S, Uhl GR. Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 1992; 32: 109-111.
26. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14: 1104-1106.
27. Leighton PW, Le Couteur DG, Pang CC, McCann SJ, Chan D, Law LK et al. The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology 1997; 49: 1577-1579.
28. Le Couteur DG, Leighton PW, McCann SJ, Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 1997; 12: 760-763.
29. Mercier G, Turpin JC, Lucotte G. Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association found. J Neurol 1999; 246: 45-47.
30. Kim JW, Kim DH, Kim SH, Cha JK. Association of the dopamine transporter gene with Parkinson's disease in Korean patients. J Korean Med Sci 2000; 15: 449-451.
31. Wang J, Liu Z, Chen B. Association between genetic polymorphism of dopamine transporter gene and susceptibility to Parkinson's disease. Zhonghua Yi Xue Za Zhi 2000; 80: 346-348.
32. Zhang L, Shao M, Xu Q, Dong X, Yang J, Li Y et al. Association between dopamine transporter gene polymorphism and Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18: 431-434.
33. Goudreau JL, Maraganore DM, Farrer MJ, Lesnick TG, Singleton AB, Bower JH et al. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Mov Disord 2002; 17: 1305-1311.
34. Lin JJ, Yueh KC, Chang DC, Chang CY, Yeh YH, Lin SZ. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not female patients. J Neurol Sci 2003; 209: 87-92.
35. Morino H, Kawarai T, Izumi Y, Kazuta T, Oda M, Komure O et al. A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. Ann Neurol 2000; 47: 528-531.
36. Nishimura M, Kaji R, Ohta M, Mizuta I, Kuno S. Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan. Mov Disord 2002; 17: 831-832.
37. Kimura M, Matsushita S, Arai H, Takeda A, Higuchi S. No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease. Ann Neurol 2001; 49: 276-277.
38. Lin CN, Liu HC, Tsai SJ, Liu TY, Hong CJ. Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G). Eur Neurol 2002; 48: 207-209.
39. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease. Mov Disord 1994; 9: 337-339.
40. Kunugi H, Kawada Y, Hattori M, Ueki A, Otsuka M, Nanko S. Association study of structural mutations of the tyrosine hydroxylase gene with schizophrenia and Parkinson's disease. Am J Med Genet 1998; 81: 131-133.
41. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002; 51: 133-136.
42. Zhao XP, Xie HJ, Tang GM, Zhao WW, Xu L, Su JJ et al. Dopamine beta hydroxylase gene polymorphism and Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20: 238-240.
43. Goridis C, Rohrer H. Specification of catecholaminergic and serotonergic neurons. Nat Rev Neurosci 2002; 3: 531-541.
44. Hotamisligil GS, Girmen AS, Fink JS, Tivol E, Shalish C, Trofatter J et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994; 9: 305-310.
45. Nakatome M, Tun Z, Shimada S, Honda K. Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease. Biochem Biophys Res Commun 1998; 247: 452-456.
46. Nanko S, Ueki A, Hattori M. No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms. Neurosci Lett 1996; 204: 125-127.
47. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993; 33: 368-372.
48. Jiang XH, Yang H, Yang JF, Dong XM, Xu QY, Chen B. Relationship between the Fnu4HI site polymorphism of monoamine oxidase A gene and Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20: 211-214.
49. Xie H, Wang X, Hao Y, Tang G, Xu L, Wu Q et al. The EcoR V polymorphism of human monoamine oxidase A is not associated with idiopathic Parkinson's disease in a Shanghai Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002; 19: 329-331.
50. Takehashi M, Tanaka S, Masliah E, Ueda K. Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci Lett 2002; 327: 79-82.
51. Costa P, Checkoway H, Levy D, Smith-Weller T, Franklin GM, Swanson PD et al. Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson's disease. Am J Med Genet 1997; 74: 154-156.
52. Wu RM, Cheng CW, Chen KH, Lu SL, Shan DE, Ho YF et al. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology 2001; 56: 375-382.
53. Shao M, Liu Z, Tao E, Chen B. Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18: 122-124.
54. Morimoto Y, Murayama N, Kuwano A, Kondo I, Yamashita Y, Mizuno Y. Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population. Am J Med Genet 1995; 60: 570-572.
55. Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995; 37: 403-405.
56. Hwang WJ, Lai ML, Tsai TT, Lai MD. Genetic polymorphism of monoamine oxidase B and susceptibility of Parkinson's disease. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 60: 137-141.
57. Herman MA, Checkoway H, O'Brien R, Costa-Mallen P, De Vivo I, Colditz GA et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology 2002; 58: 1381-1387.
58. Mellick GD, Buchanan DD, McCann SJ, James KM, Johnson AG, Davis DR et al. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14: 219-224.
59. Mellick GD, Buchanan DD, Silburn PA, Chan DK, Le Couteur DG, Law LK et al. The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population. J Neurol. 2000; 247: 52-55.
60. Tan EK, Chai A, Lum SY, Shen H, Tan C, Teoh ML et al. Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population. Am J Med Genet 2003; 120: 58-62.
61. Kopin I. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 1985; 37: 334-364.
62. Smit N, Pavel S, Kammeyer A, Westerhof W. Determination of catechol-O-methyltransferase activity in relation to melanin metabolism using high performance liquid chromatography with fluorimetric detection. Anal Biochem 1990; 190: 286-291.
63. Mannisto P, Ulmagen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C et al. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992; 39: 291-350.
64. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neuroscience Lett 1997; 221: 202-204.
65. Yoritaka A, Hattori N, Yoshino H, Mizuno Y. Catechol-O-methyltransferase genotype and susceptibility for Parkinson's disease in Japan. J Neural Transm 1997; 104: 1313-1317.
66. Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, al-Chalabi A et al. No association between Parkinson's disease and low-activity alleles of catechol-O-methyltransferase. Biochem Biophys Res Commun 1996; 228: 780-784.
67. Xie T, Ho SL, Li LS, Ma OC. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 1997; 12: 426-427.
68. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 1997; 7: 65-71.
69. Eerola J, Launes J, Hellstrom O, Tienari PJ. Apolipoprotein E (APOE), parkin and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland. Neurosci Lett 2002; 330: 296-298.
70. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994; 102(Suppl 9): 55-61.
71. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Adv Neurol 1996; 69: 61-72.
72. McCann SJ, Pond SM, James KM, Le Couteur DG. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 1997; 153: 50-53.
73. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998; 8: 227-238.
74. Christensen PM, Gotzsche PC, Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics 1998; 8: 473-479.
75. Persad AS, Stedeford T, Tanaka S, Chen L, Banasik M. Parkinson's disease and CYP2D6 polymorphism in Asian populations: a meta-analysis. Neuroepidemiology 2003; 22: 357-361.
76. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Mov Disord 1998; 13: 212-220.
77. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 2: 1213-1216.
78. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996; 272: 199-210.
79. Woo SI, Kim JW, Seo HG, Park CH, Han SH, Kim SH et al. CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psychiatry Clin Neurosci 2001; 55: 373-377.
80. Harhangi BS, Oostra BA, Heutink P, van Duijn CM, Hofman A, Breteler MM. CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study. Mov Disord 2001; 16: 290-293.
81. Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov Disord 2000; 15: 714-719.
82. Chida M, Yokoi T, Kosaka Y, Chiba K, Nakamura H, Ishizaki T et al. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 1999; 9: 601-605.
83. Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, Fabbrini G et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999; 53: 1415-1421.
84. Joost O, Taylor CA, Thomas CA, Cupples LA, Saint-Hilaire MH, Feldman RG et al. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease. Mov Disord 1999; 14: 590-595.
85. Sabbagh N, Brice A, Marez D, Durr A, Legrand M, Lo Guidice JM et al. CYP2D6 polymorphism and Parkinson's disease susceptibility. Mov Disord 1999; 14: 230-236.
86. Payami H, Lee N, Zareparsi S, Gonzales McNeal M, Camicioli R, Bird TD et al. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology 2001; 56: 1363-1370.
87. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress-induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001; 40: 959-975.
88. Wu RM, Cheng CW, Chen KH, Shan DE, Kuo JW, Ho YF et al. Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese. J Neural Transm 2002; 109: 1403-1414.
89. Wang J, Liu Z, Chen B. Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson's disease. Zhonghua Yi Xue Za Zhi 2000; 80: 585-587.
90. Wang J, Liu Z, Chan P. Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson's disease in a Chinese population. Mov Disord 2000; 15: 1267-1269.
91. Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I. Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson's disease. J Neural Transm Gen Sect 1996; 103: 843-849.
92. Chan DK, Mellick GD, Buchanan DD, Hung WT, Ng PW, Woo J et al. Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population. J Neural Transm 2002; 109: 35-39.
93. Stroombergen MCMJ, Waring RH. Determination of glutathione S-transferase μ and θ polymorphisms in neurological disease. Hum Exp Toxicol 1999; 18: 141-145.
94. De Palma G, Mozzoni P, Mutti A, Calzetti S, Negrotti A. Case-control study of interactions between genetic and environmental factors in Parkinson's disease. Lancet 1998; 352: 1986-1987.
95. Ahmadi A, Fredrikson M, Jerregard H, Akerback A, Fall PA, Rannug A et al. GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem Biophys Res Commun 2000; 269: 676-680.
96. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Conuteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998; 352: 1344-1346.
97. Rahbar A, Kempkes M, Muller T, Reich S, Welter FL, Meves S et al. Glutathione S-transferase polymorphism in Parkinson's disease. J Neural Transm 2000; 107: 331-334.
98. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 2001; 288: 887-892.
99. Kelada SN, Stapleton PL, Farin FM, Bammler TK, Eaton DL, Smith-Weller T et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease. Neurosci Lett 2003; 337: 5-8.
100. Bialecka M, Gawronska-Szklarz B, Drozdzik M, Honczarenko K, Stankiewicz J et al. N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population. Eur J Clin Pharmacol 2002; 57: 857-862.
101. Agundez JAG, Jimenez-Jimenez FJ, Luengo A et al. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 1998; 51: 1587-1591.
102. Harhangi BS, Oostra BA, Heutink P, van Duijn CM, Hofman A, Breteler MM. N-acetyltransferase 2 polymorphism in Parkinson's disease: the Rotterdam study. J Neurol Neurosurg Psychiatry 1999; 67: 518-520.
103. Nicholl DJ, Bennett P. Acetylator genotype and Parkinson's disease. Lancet 1998; 351: 141-142.
104. Van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL et al. Genetic polymorphisms of the N-acetyltransferase gene and risk of Parkinson's disease. Neurology 2003; 60: 1189-1191.
105. Arai H, Muramatsu T, Higuchi S, Sasaki H, Trojanowski JQ. Apolipoprotein E gene in Parkinson's disease with or without dementia. Lancet 1994; 343: 889.
106. Arai H, Higuchi S, Sasaki H. Apolipoprotein E genotype and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology 1997; 43(Suppl 1): 2-10.
107. Inzelberg R, Paleacu D, Chapman J, Korczyn AD. Apolipoprotein E and Parkinson's disease. Ann Neurol 1998; 44: 294.
108. Tang G, Xie H, Xu L, Hao Y, Lin D, Ren D. Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. Am J Med Genet 2002; 114: 446-449.
109. Hardy J, Crook R, Prihar G, Roberts G, Raghavan R, Perry R. Senile dementia of the lewy body type has an apolipoprotein E epsilon 4-allele frequency intermediate between controls and Alzheimer's disease. Neurosci Lett 1994; 182: 1-2.
110. Rubinsztein DC, Hanlon CS, Irving RM, Goodburn S, Evans DG, Kellar-Wood H et al. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset alzheimer's disease. Mol Cell Probes 1994; 8: 519-525.
111. Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK et al. Influence of apolioprotein E genotype on senile dementia of the Alzheimer and Lewy body types: significance for etiological theories of Alzheimer's disease. Am J Pathol 1994; 145: 1472-1484.
112. Marder K, Maestre G, Cote L, Mejia H, Alfaro B, Halim A et al. The apolipoprotein E4 allele in Parkinson's disease with and without dementia. Neurology 1994; 44: 1330-1331.
113. Benjamin R, Leake A, Edwardson JA, McKeith IG, Ince PG, Perry RH et al. Apolioprotein E genes in Lewy body and Parkinson's disease. Lancet 1994; 343: 1565.
114. Koller WC, Glatt SL, Hubble JP, Paolo A, Troster AI, Handler MS et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995; 37: 242-245.
115. Ibarreta D, Gomez-Isla T, Portera-Sanchez A, Parrilla R, Ayuso MS. Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. J Neurol Sci 1995; 134: 146-149.
116. Martinoli MG, Trojanowski JQ, Schmidt ML, Arnold SE, Fujiwara TM, Lee VM et al. Association of apoplipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol 1995; 90: 239-243.
117. Poduslo SE, Riggs D, Rolan T, Schwanhaus J. Apolipoprotein E and B alleles in Parkinson's disease. Neurosci Lett 1995; 194: 145-147.
118. Morris CM, Massey HM, Benjamin R, Leake A, Broadbent C, Griffiths M et al. Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias. J Neural Transm Suppl 1996; 47: 205-218.
119. Helisalmi S, Linnaranta K, Lehtovirta M, Mannermaa A, Heinonen O, Ryynanen M et al. Apolioprotein E polymorphism in patients with different neurodegenerative disorders. Neurosci Lett 1996; 205: 61-64.
120. Whitehead AS, Bertrandy S, Finnan F, Butler A, Smith GD, Ben-Shlomo Y. Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 341-351.
121. Egensperger R, Bancher C, Kosel S, Jellinger K, Mehraein P, Graeber MB. The apolioprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun 1996; 224: 484-486.
122. St. Clair D. Apolipoprotein E gene in Parkinson's disease, Lewy body dementia and Alzheimer's disease. J Neural Transm 1997; 51(Suppl): 161-165.
123. Ballering LAP, Steffens-Nakken HM, Esselink RAJ, De Vos RAI, Jansen Steur ENH, Vermes I. Apolipoprotein E genotype in patients with neurodegenerative diseases. Clin Biochem 1997; 30: 405-411.
124. Wakabayashi K, Kakita A, Hayashi S, Okuizumi K, Onodera O, Tanaka H et al. Apolioprotein E E4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol 1998; 95: 450-454.
125. Mattila PM, Koskela T, Roytta M, Lehtimaki T, Pirttila TA, Ilveskoski E et al. Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology. Acta Neuropathol (Berl) 1998; 96: 417-420.
126. Fuente-Fernandez RDL, Sellers A, Beyer K, Lao JI. Apolioprotein E genotypes and age at onset of Parkinson's disease. Ann Neurol 1998; 44: 294-295.
127. Oliveri RL, Nicoletti G, Cittadella R, Manna I, Branca D, Zappia M et al. Apolipoprotein E polymorphisms and Parkinson's disease. Neurosci Lett 1999; 277: 83-86.
128. Hao Y, Xie H, Xu L. Association between polymorphism of alpha 1-antichymotrypsin and apolipoprotein E gene and Parkinson's disease in Shanghai Hans. Zhonghua Yi Xue Za Zhi 2001; 81: 1172-1175.
129. Khan N, Graham E, Dixon P, Morris C, Mander A, Clayton D et al. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol 2001; 49: 665-668.
130. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002; 79: 458-461.
131. Kruger R, Vieira-Saecker AM, Kuhn W, Berg D, Muller T, Kuhnl N et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann Neurol 1999; 45: 611-617.
132. Bon MAM, Jansen Steur ENH, de Vos RAI, Vermes I. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. Neurosci Lett 1999; 266: 149-151.
133. Kosel S, Lucking CB, Egensperger R, Mehraein P, Graeber MB. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 1996; 44: 174-183.
134. Ikebe S, Tanaka M, Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 190; 28: 281-295.
135. Bandmann O, Sweeney MG, Danial SE, Marsden CD, Wood NW. Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 1997; 24: 262-265.
136. Egensperger R, Kosel S, Schnopp NM, Mehraein P, Graeber MB. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol Appl Neurobiol 1997; 23: 315-321.
137. Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993; 17: 171-184.
138. Brown MD, Shoffner JM, Kim YL, Jun AS, Graham BH, Cabell MF et al. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Am J Med Genet 1996; 61: 283-289.
139. Van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003; 72: 804-811.
140. Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol 2003; 250(Suppl 3): III40-III43.
141. Hakansson A, Melke J, Westberg L, Shahabi HN, Buervenich S, Carmine A et al. Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population. Ann Neurol 2003; 53: 823.
142. Hong CJ, Liu HC, Liu TY, Lin CH, Cheng CY, Tsai SJ. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci Lett 2003; 353: 75-77.
143. Masaki T, Matsushita S, Arai H, Takeda A, Itoyama Y, Mochizuki H et al. Association between a polymorphism of brain-derived neurotrophic factor gene and sporadic Parkinson's disease. Ann Neurol 2003; 54: 276-277.
144. Wartiovaara K, Hytonen M, Vuori M, Paulin L, Rinne J, Sariola H. Mutation analysis of the glial cell line-delivered neurotrophic factor gene in Parkinson's disease. Exp Neurol 1998; 152: 307-309.
145. Parboosingh JS, Rousseau M, Rogan F, Amit Z, Chertkow H, Johnson WG et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol 1995; 52: 1160-1163.
146. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 1996; 226: 561-565.
147. Grasbon-Frodl EM, Kosel S, Riess O, Muller U, Mehraein P, Graeber MB. Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. Biochem Biophys Res Commun 1999; 255: 749-752.
148. Farin FM, Hitosis Y, Hallagan SE, Kushleika J, Woods JS, Janssen PS et al. Genetic polymorphisms of superoxide dismutase in Parkinson's disease. Mov Disord 2001; 16: 705-707.
149. Hughes AJ, Dniel SE, Kilford L, Lees AJ. Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
150. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000; 54: 1195-1198.
151. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M et al. Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet. 2001; 10: 1847-1851.
152. Mizuta I, Nishimura M, Mizuta E, Yamasaki S, Ohta M, Kuno S. Meta-analysis of alpha synuclein/ NACP polymorphism in Parkinson's disease in Japan. J Neurol Neurosurg Psychiatry 2002; 73: 350.
153. Izumi Y, Morino H, Oda M, Maruyama H, Udaka F, Kameyama M et al. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. Neurosci Lett 2001; 300: 125-127.
154. Ross OA, Awayn NH, McWhinney D, Maxwell LD, El-Agnaf ÒM, Barnett YA et al. A novel polymorphic triplet repeat in intron five of the alpha-synuclein gene: no evidence of expansion or allelic association with idiopathic Parkinson's disease in the Irish. Neuroreport 2002; 13: 1621-1625.
155. Tan EK, Tan C, Shen H, Chai A, Lum SY, Teoh ML et al. Alpha-synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci Lett 2003; 336: 70-72.
156. Holzmann C, Kruger R, Saecker AM, Schmitt I, Schols L, Berger K et al. Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease. J Neural Transm 2003; 110: 67-76.
157. Spadafora P, Annesi G, Pasqua AA, Serra P, Ciro Candiano IC, Carrideo S et al. NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy. Neurosci Lett 2003; 351: 75-78.
158. Wang M, Hattori N, Matsumine H, Kobayashi T, Yoshino H, Morioka A et al. Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann Neurol. 1999; 45: 655-658.
159. Satoh J, Kuroda Y. Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease. Neuroreport 1999; 10: 2735-2739.
160. West AB, Maraganore D, Crook J, Lesnick T, Lockhart PJ, Wilkes KM et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum Mol Genet 2002; 11: 2787-2792.
161. Lincoln SJ, Maraganore DM, Lesnick TG, Bounds R, de Andrade M, Bower JH et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord. 2003; 18: 1306-1311.
162. Peng R, Gou Y, Yuan Q, Li T, Latsoudis H, Yuan G et al. Mutation screening and association analysis of the parkin gene in Parkinson's disease patients from South-West China. Eur Neurol. 2003; 49: 85-89.
163. Lucking CB, Chesneau V, Lohmann E, Verpillat P, Dulac C, Bonnet AM et al. Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch Neurol 2003; 60: 1253-1256.
164. Mellick GD, Buchanan DD, Hattori N, Brookes AJ, Mizuno Y, Le Couteur DG et al. The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. Parkinsonism Relat Disord 2001; 7: 89-91.
165. Hu CJ, Sung SM, Liu HC, Lee CC, Tsai CH, Chang JG. Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan. Eur Neurol 2000; 44: 90-93.
166. Mata IF, Alvarez V, Garcia-Moreira V, Guisasola LM, Ribacoba R, Salvador C et al. Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neurosci Lett. 2002; 329: 149-152.
167. Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC et al. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003; 60: 975-980.
168. Zhang J, Hattori N, Leroy E, Morris HR, Kubo S, Kobayashi T et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord 2000; 6: 195-197.
169. Satoh J, Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci 2001; 189: 113-117.
170. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999; 53: 1858-1860.
171. Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 2000; 11: 2079-2082.
172. Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Correze JR et al. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov Disord 2003; 18: 130-137.
173. Mellick GD, Silburn PA. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci Lett 2000; 293: 127-130.
174. Wang J, Zhao CY, Si YM, Liu ZL, Chen B, Yu L. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov Disord 2002; 17: 767-771.
175. Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 2002; 58: 881-884.
176. Zheng K, Heydari B, Simon DK. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch Neurol 2003; 60: 722-725.
177. Carmine A, Buervenich S, Galter D, Jonsson EG, Sedvall GC, Farde L et al. NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits. Am J Med Genet 2003; 120: 51-57.
178. Tan EK, Chung H, Zhao Y, Shen H, Chandran VR, Tan C et al. Genetic analysis of Nurr1 haplotypes in Parkinson's disease. Neurosci Lett 2003; 347: 139-142.
179. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1: 345-349.
180. Fahn S. Fluctuations of disability in Parkinson's disease: pathopysiological aspects. In: Marsden CD, Fahn S (eds). Movement Disorders. Butterworth Scientific: London 1982; pp 123-145.
181. Nutt JG. Levodopa-incluced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-345.
182. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993; 60: 698-702.
183. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189-193.
184. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12.
185. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989; 25: 523-526.
186. Wu M, Brudzynski SM, Mogenson GJ. Functional interaction of dopamine and glutamate in the nucleus accumbens in the regulation of locomotion. Can J Physiol Pharmacol 1993; 71: 407-413.
187. Hely MA, Morris JG, Reid WG, O'Sullivan DJ, Williamson PM, Broe GA et al. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995; 92: 455-463.
188. Nutt JG, Woodward WR, Carter JH, Trotman TL. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosury Psychiatry 1989; 52: 481-487.
189. Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001; 56: 1757-1759.
190. Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 2000; 10: 43-48.
191. Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 2001; 58: 209-213.
192. Wang J, Liu ZL, Chen B. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease. Neurosci Lett 2001; 308: 21-24.
193. Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I et al. L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750-1755.
194. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet 1999; 56: 394-399.
195. Wang J, Si YM, Liu ZL, Yu L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics 2003; 13: 365-369.
196. de la Fuente-Fernandez R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol 1999; 22: 226-230.
197. Reilly DK, Rivera-Calimlim L, Van Dyke D. Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 1980; 28: 278-286.
198. Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 1984; 35: 804-809.
199. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000; 23: 143-148.
200. Lee JJ, Chang CK, Liu IM, Chi TC, Yu HJ, Cheng JT. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298: 131-134.